Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. Friday, Sanofi reported that Dupixent had set a ...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Sanofi stock is up 21.89% year-to-date. Its eight-day, 20-day, 50-day and even 200-day moving averages all point higher. The stock also completed a Golden Cross, where the 50-day moving average ...
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment TARRYTOWN, N ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results